NASDAQ: DERMJourney Medical Corp Stock
$5.74+0.17 (+3.05%)
Updated Mar 21, 2025
DERM Price
$5.74
Fair Value Price
N/A
Market Cap
$119.91M
52 Week Low
$2.85
52 Week High
$6.89
P/E
-6.11x
P/B
10.97x
P/S
2.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$57.77M
Earnings
-$18.34M
Gross Margin
57.3%
Operating Margin
-28.24%
Profit Margin
-31.7%
Debt to Equity
4.86
Operating Cash Flow
-$28M
Beta
0.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DERM Overview
Journey Medical Corporation develops and commercializes pharmaceuticals to treat dermatological conditions in the U.S. Products include Qbrexza, Accutane, Targadox, Ximino, and Exelderm. Journey Medical also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. Formerly known as Coronado Dermatology, Inc., the company was incorporated in 2014 and is headquartered in Scottsdale, AZ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DERM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
DERM
Ranked#40 of 57
Ranked#40 of 57
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $21.90 | A | |
| $34.60 | A | |
| $4.88 | A |
Be the first to know about important DERM news, forecast changes, insider trades & much more!
DERM News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DERM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DERM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DERM is poor value based on its book value relative to its share price (10.97x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.23x)
P/B vs Industry Valuation
DERM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DERM due diligence checks available for Premium users.
Valuation
DERM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.11x
Industry
10.68x
Market
31.55x
DERM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.97x
Industry
2.23x
DERM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DERM's financial health
Profit margin
Revenue
$14.6M
Net Income
-$2.4M
Profit Margin
-16.3%
DERM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DERM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$64.0M
Liabilities
$53.1M
Debt to equity
4.86
DERM's short-term assets ($46.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DERM's short-term assets ($46.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DERM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
$0.0
Financing
-$294.0k
DERM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DERM vs Pharmaceutical Stocks
Journey Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.